The role of positron emission tomography-computed tomography/magnetic resonance imaging in the management of sarcoidosis patients

Hellenic Journal of Nuclear Medicine

Volumn 17, Issue 2, 2014, Pages 123-135

  Promteangtrong, Chetsadaporn ^a,b   Salavati, Ali ^a   Cheng, Gang ^a   Torigian, Drew A ^a   Alavi, Abass ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHULABHORN GRADUATE INSTITUTE   (Thailand)

Author keywords

Lymphoma sarcoidosis; Management; Occult sarcoidosis; PET MRI

Indexed keywords

FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; SARCOIDOSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84905858649     PISSN: 17905427     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (116)

1. Statement on Sarcoidosis. American Journal of Respiratory and Critical Care Medicine 1999; 160: 736-55. 10.1164/ajrccm.160.2.ats4-99 10.1164/ajrccm.160.2.ats4-99.
2. Hem E. [Multiple benign sarcoid of the skin-100 years since Caesar Boeck's pioneering article]. Tidsskrift for den Norske laegeforening 1999; 119: 4567-9.
3. Pietinalho A, Hiraga Y, Hosoda Y et al. The frequency of sarcoidosis in Finland and Hokkaido, Japan. A comparative epidemiological study. Sarcoidosis 1995; 12: 61-7.
4. Hamzeh N. Sarcoidosis. The Medical clinics of North America 2011; 95: 1223-34. 10.1016/j.mcna.2011.08.004 10.1016/j.mcna.2011.08.004.
5. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007; 357: 2153-65. 10.1056/NEJMra071714 10.1056/NEJMra071714.
6. Haimovic A, Sanchez M, Judson MA, Prystowsky S. Sarcoidosis: a comprehensive review and update for the dermatologist: part I. Cutaneous disease. J Am Acad Dermatol 2012; 66(5): 699 e1-18; quiz 717-8. S0190-9622(12)00109-0 [pii]. 10.1016/j.jaad.2011.11.965 [doi] S0190-9622(12)00109-0 [pii]. 10.1016/j.jaad.2011.11.965 [doi].
7. Iannuzzi MC, Fontana JR. Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. JAMA 2011; 305(4): 391-9. 305/4/391 [pii]. 10.1001/jama.2011.10 [doi] 305/4/391 [pii]. 10.1001/jama.2011.10 [doi].
8. Oki M, Saka H, Kitagawa C et al. Real-time endobronchial ultra sound-guided transbronchial needle aspiration is useful for diagnosing sarcoidosis. Respirology 2007; 12: 863-8. 10.1111/j.1440-1843.2007.01145.x 10.1111/j.1440-1843.2007.01145.x.
9. Navani N, Booth HL, Kocjan G et al. Combination of endobronchial ultrasound-guided transbronchial needle aspiration with standard bronchoscopic techniques for the diagnosis of stage I and stage II pulmonary sarcoidosis. Respirology 2011; 16(3): 467-72. 10.1111/j.1440-1843. 2011.01933.x [doi] 10.1111/j.1440-1843.2011.01933.x [doi].
10. Costabel U, Ohshimo S, Guzman J. Diagnosis of sarcoidosis. Current opinion in pulmonary medicine 2008; 14: 455-61. 10.1097/MCP.0b013e3283056a61 10.1097/MCP.0b013e3283056a61.
11. Kwee TC, Torigian DA, Alavi A. Oncological applications of positron emission tomography for evaluation of the thorax. J Thorac Imaging 2013; 28: 11-24. 10.1097/RTI.0b013e318279449b 10.1097/RTI.0b013e318279449b.
12. 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med 2012; 53: 241-8. 10.2967/jnumed.111.090662 10.2967/jnumed.111.090662.
13. Kwee TC, Torigian DA, Alavi A. Nononcological applications of positron emission tomography for evaluation of the thorax. J Thorac Imaging 2013; 28(1): 25-39. 10.1097/RTI.0b013e31827882a9 [doi]. 00005382-201301000-00006 [pii] 10.1097/RTI.0b013e31827882a9 [doi]. 00005382-201301000-00006 [pii].
14. Miyara M, Amoura Z, Parizot C et al. The immune paradox of sarcoidosis and regulatory T cells. J Exp Med 2006; 203: 359-70. 10.1084/jem.20050648 10.1084/jem.20050648.
15. O'Neill LA, Hardie DG. Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature 2013; 493: 346-55. 10.1038/nature11862 10.1038/nature11862.
16. 18F]fluoro-2-deoxy-D- glucose as a potential in vitro agent for labelling human granulocytes for clinical studies by positron emission tomography. International journal of radiation applications and instrumentation Part B. Nuclear medicine and biology 1992; 19: 183-90.
17. Kubota R, Yamada S, Kubota K et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992; 33: 1972-80.
18. 18F]- fluorodeoxyglucose uptake in abdominal abscesses: a PET study. J Comput Assist Tomogr 1989; 13(5): 829-31.
19. 18F]FDG in brain abscess: a PET study. J Comput Assist Tomogr 1990; 14: 486-7.
20. Bissonnette R, Tardif JC, Harel F et al. Effects of the tumor necrosis factor-alpha antagonist adalimumab on arterial inflammation assessed by positron emission tomography in patients with psoriasis: results of a randomized controlled trial. Circulation Cardiovascular imaging 2013; 6: 83-90. 10.1161/CIRCIMAGING.112.975730 10.1161/CIRCIMAGING.112.975730.
21. 18FDG PET-CT imaging detects arterial inflammation and early atherosclerosis in HIV-infected adults with cardiovascular disease risk factors. Journal of Inflammation 2012; 9: 26. 10.1186/1476-9255-9-26 10.1186/1476-9255-9-26.
22. 18F-FDG PET CT imaging enhances assessment of atherosclerotic plaque inflammation. Nucl Med Commun 2013; 34(9): 860-7. 10.1097/MNM.0b013e3283637512 [doi] 10.1097/MNM.0b013e3283637512 [doi].
23. Subramanian S, Tawakol A, Burdo TH et al. Arterial inflammation in patients with HIV. JAMA 2012; 308(4): 379-86. 1221700 [pii]. 10.1001/jama.2012.6698 [doi] 1221700 [pii]. 10.1001/jama.2012.6698 [doi].
24. Dweck MR, Jones C, Joshi NV et al. Assessment of valvular calcification and inflammation by positron emission tomography in patients with aortic stenosis. Circulation 2012; 125: 76-86. 10.1161/CIRCULATIONAHA.111.051052 10.1161/CIRCULATIONAHA.111.051052.
25. Yamashita H, Kubota K, Takahashi Y et al. Similarities and differences in fluorodeoxyglucose positron emission tomography/computed tomography findings in spondyloarthropathy, polymyalgia rheumatica and rheumatoid arthritis. Joint Bone Spine 2013; 80: 171-7. 10.1016/j.jbspin.2012.04.006 10.1016/j.jbspin.2012. 04.006.
26. Abdulla S, Salavati A, Saboury B et al. Quantitative assessment of global lung inflammation following radiation therapy using FDG PET/CT: a pilot study. Eur J Nucl Med Mol Imaging 2014; 41: 350-6. 10.1007/s00259-013-2579-4 10.1007/s00259-013-2579-4.
27. Vos FJ, Bleeker-Rovers CP, Oyen WJ. The use of FDG-PET/CT in patients with febrile neutropenia. Seminars in nuclear medicine 2013; 43: 340-8. 10.1053/j.semnuclmed.2013.04.007 10.1053/j.semnuclmed.2013.04.007.
28. Balan A, Hoey ET, Sheerin F et al. Multi-technique imaging of sarcoidosis. Clin Radiol 2010; 65: 750-60. 10.1016/j.crad.2010.03.014 10.1016/j.crad.2010.03.014.
29. Scadding JG. Sarcoidosis, with Special Reference to Lung Changes. Br Med J 1950; 1(4656): 745-53.
30. Oberstein A, von Zitzewitz H, Schweden F, Muller-Quernheim J. Non invasive evaluation of the inflammatory activity in sarcoidosis with high-resolution computed tomography. Sarcoidosis Vasc Diffuse Lung Dis 1997; 14: 65-72. (Pubitemid 27170557)
31. 18F-labeled fluoro-2-deoxy-D-glucose positron emission tomography. Clin Chest Med 1997; 18(4): 799-811.
32. Sulavik SB, Spencer RP, Weed DA et al. Recognition of distinctive patterns of gallium-67 distribution in sarcoidosis. J Nucl Med 1990; 31: 1909-14.
33. 67Ga images in the noninvasive diagnosis of sarcoidosis. Chest 1993; 103: 403-9.
34. Mana J, Gamez C. Molecular imaging in sarcoidosis. Current opinion in pulmonary medicine 2011; 17: 325-31. 10.1097/MCP.0b013e3283480d36 10.1097/MCP.0b013e3283480d36.
35. Jain V, Hasselquist S, Delaney MD. PET scanning in sarcoidosis. Ann N Y Acad Sci 2011; 1228: 46-58. 10.1111/j.1749-6632.2011.06075.x [doi] 10.1111/j.1749-6632.2011.06075.x [doi].
36. 67Ga scintigraphy in patients with sarcoidosis. J Nucl Med 2006; 47: 1571-6. 47/10/1571 [pii] 47/10/1571 [pii].
37. Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med 1994; 35: 1647-9.
38. 18F-FDG PET/CT in sarcoidosis management: review and report of 20 cases. Eur J Nucl Med Mol Imaging 2008; 35: 1537-43. 10.1007/s00259-008-0770-9 10.1007/s00259-008- 0770-9.
39. Teirstein AS, Machac J, Almeida O et al. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest 2007; 132: 1949-53. 10.1378/chest.07-1178 10.1378/chest.07-1178.
40. Mostard RL, Voo S, van Kroonenburgh MJ et al. Inflammatory activity assessment by F18 FDG-PET/CT in persistent symptomatic sarcoidosis. Respiratory medicine 2011; 105: 1917-24. 10.1016/j.rmed.2011.08.01210.1016/j.rmed.2011.08. 012.
41. Rubini G, Cappabianca S, Altini C et al. Current clinical use of FDG-PET/CT in patients with thoracic and systemic sarcoidosis. Radiol Med 2014; 119(1): 64-74. 10.1007/s11547-013-0306-7 [doi] 10.1007/s11547-013-0306-7 [doi].
42. Sobic-Saranovic DP, Grozdic IT, Videnovic-Ivanov J et al. Responsiveness of FDG PET/CT to treatment of patients with active chronic sarcoidosis. Clin Nucl Med 2013; 38(7): 516-21. 10.1097/RLU.0b013e31828731f5[doi] 10.1097/RLU.0b013e31828731f5 [doi].
43. 18F-FDG PET/CT for diagnosis and adjustment of therapy in patients with active chronic sarcoidosis. J Nucl Med 2012; 53:1543-9. 10.2967/jnumed.112.10438010.2967/jnumed. 112.104380.
44. Muller NL, Mawson JB, Mathieson JR et al. Sarcoidosis: correlation of extent of disease at CT with clinical, functional, and radiographic findings. Radiology 1989; 171: 613-8. 10.1148/radiology.171.3.2717730 10.1148/radiology. 171.3.2717730.
45. Jain V, Hasselquist S, Delaney MD. PET scanning in sarcoidosis. Ann N Y Acad Sci 2011; 1228: 46-58. 10.1111/j.1749-6632.2011.06075.x 10.1111/j.1749-6632.2011.06075.x.
46. 18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis. Eur J Nucl Med Mol Imaging 2009; 36: 1131-7. 10.1007/s00259-009-1097-x 10.1007/s00259-009- 1097-x.
47. 18F-FDG PET patterns and BAL cell profiles in pulmonary sarcoidosis. Eur J Nucl Med Mol Imaging 2010; 37: 1181-8. 10.1007/ s00259-009-1376-6 10.1007/s00259-009-1376-6.
48. 18F-FDG PET in sarcoidosis: an observational study in 12 patients treated with inflix imab. Sarcoidosis Vasc Diffuse Lung Dis 2008; 25: 143-9.
49. 18F-FDG PET activity in sarcoidosis. Respir Med 2013; 107(3):439-47. S0954-6111(12)00422-2 [pii]. 10.1016/j.rmed.2012.11. 011 [doi] S0954-6111(12)00422-2 [pii]. 10.1016/j.rmed.2012.11.011 [doi].
50. 18F-FDG PET/CT for the assessment of disease extension and activity in patients with sarcoidosis: results of a preliminary prospective study. Clin Nucl Med 2013; 38(4): e171-7. 10.1097/RLU.0b013e31827a27df [doi] 10.1097/RLU.0b013e31827a27df [doi].
51. Cooper LT, Baughman KL, Feldman AM et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. Eur Heart J 2007; 28: 3076-93. ehm456 [pii]. 10.1093/eurheartj/ehm456 [doi] ehm456 [pii]. 10.1093/eurheartj/ehm456 [doi].
52. Tahara N, Tahara A, Nitta Y et al. Heterogeneous myocardial FDG up take and the disease activity in cardiac sarcoidosis. JACC Cardiovas cular imaging 2010; 3: 1219-28. 10.1016/j.jcmg.2010.09.015 10.1016/j.jcmg.2010.09.015.
53. 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging 2008; 35: 933-41. 10.1007/s00259-007-0650-8 10.1007/s00259-007-0650-8.
54. 18F-FDG PET-CT in the detection of cardiac sarcoidosis. J Nucl Cardiol 2009; 16: 801-10. 10.1007/s12350-009-9110-0 10.1007/s12350-009- 9110-0.
55. 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 2004; 45: 1989-98. 45/12/1989 [pii] 45/12/1989 [pii].
56. 18F-fluoro-2-de oxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J 2005; 26: 1538-43.10.1093/eurheartj/ehi180 10.1093/eurheartj/ehi180.
57. 18F-FDG PET. J Nucl Med 2003; 44: 1030-6.
58. Keijsers RG, Verzijlbergen FJ, Rensing BJ, Grutters JC. Cardiac sarcoidosis: a challenge to measure disease activity. J Nucl Cardiol 2008; 15: 595-8. 10.1016/j.nuclcard.2008.02.033 10.1016 /j.nuclcard.2008.02.033.
59. 18F-FDG PET-CT. J Nucl Cardiol 2012; 19: 807-10. 10.1007/s12350-012-9550-9 10.1007/s12350-012-9550-9.
60. Casset-Senon D, Philippe L, Renard JP, Cosnay P. Recurrent ventricular tachycardia in cardiac sarcoidosis: usefulness of fluorodeoxyglucose positron emission tomography for adequate management of corticoid therapy after placement of an implantable cardioverter defibrillator. J Nucl Cardiol 2008; 15: 282-5. 10.1016/j.nuclcard.2008.01.006 10.1016/j.nuclcard.2008.01.006.
61. Takeda N, Yokoyama I, Hiroi Y et al. Positron emission tomography predicted recovery of complete A-V nodal dysfunction in a patient with cardiac sarcoidosis. Circulation 2002; 105: 1144-5. (Pubitemid 34212627)
62. Mc Ardle BA, Leung E, Ohira H et al. The role of F(18)-fluorodeoxyglucose positron emission tomography in guiding diagnosis and management in patients with known or suspected cardiac sarcoidosis. J Nucl Cardiol 2013; 20: 297-306. 10.1007/s12350-012-9668-9 10.1007/s12350-012-9668-9.
63. 18F-FDG PET/CT for the assessment of myocardial sarcoidosis. Curr Cardiol Rep 2013; 15(4): 352. 10.1007/s11886-013-0352-8 [doi] 10.1007/s11886-013-0352-8 [doi].
64. 18F-FDG uptake and for evaluating active lesions of cardiac sarcoidosis. EJNMMI Res 2014; 4(1): 1. 2191-219X-4-1 [pii]. 10.1186/2191-219X-4-1 [doi] 2191-219X-4-1 [pii]. 10.1186/2191-219X-4-1 [doi].
65. Dubey N, Miletich RS, Wasay M et al. Role of fluorodeoxyglucose positron emission tomography in the diagnosis of neurosarcoidosis. J Neurol Sci 2002; 205: 77-81. S0022510X02002253 [pii] S0022510X02002253 [pii].
66. Bolat S, Berding G, Dengler R et al. Fluorodeoxyglucose positron emission tomography (FDG-PET) is useful in the diagnosis of neurosarcoidosis. J Neurol Sci 2009; 287: 257-9. 10.1016/j.jns.2009.08.060 10.1016/j.jns.2009.08.060.
67. 18F]- fluorodeoxyglucose-positron emission tomography/CT scanning in the diagnosis of neurosarcoidosis. J Clin Neurosci 2012; 19: 1461-2. 10.1016/j.jocn.2012.02.013 10.1016/j.jocn.2012.02.013.
68. Bartels S, Kyavar L, Blumstein N et al. FDG PET findings leading to diagnosis of neurosarcoidosis. Clin Neurol Neurosurg 2013; 115: 85-8. 10.1016/j.clineuro.2012.03.042 10.1016/j.clineuro.2012.03.042.
69. Asabella AN, Gatti P, Notaristefano A et al. F-18 FDG PET/CT in the diagnosis of a rare case of neurosarcoidosis in a patient with diabetes insipidus. Clin Nucl Med 2011; 36: 795-7. 10.1097/RLU.0b013e318219b28b 10.1097/RLU.0b013e318219b28b.
70. 18F]-FDG PET and early metabolic response to corticosteroid therapy. Br J Radiol 2007; 80: e67-71.10.1259/bjr/ 33076108 10.1259/bjr/33076108.
71. Huang JF, Aksamit AJ, Staff NP. MRI and PET imaging discordance in neurosarcoidosis. Neurology 2012; 79: 1070. 10.1212/WNL.0b013e3182684672 10.1212/WNL.0b013e3182684672.
72. 18F]-fluorodeoxyglucose- positron emission tomography in patients with active myelopathy. Mayo Clinic proceedings 2013; 88: 1204-12. 10.1016/j.mayocp.2013.07.019 10.1016/j.mayocp. 2013.07.019.
73. Sakushima K, Yabe I, Shiga T et al. FDG-PET SUV can distinguish be tween spinal sarcoidosis and myelopathy with canal stenosis. J Neurol 2011; 258: 227-30. 10.1007/s00415-010-5729-7 10.1007/s00415-010-5729-7.
74. 18F-FDG PET as a predictor of pulmonary function in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28(2): 123-9.
75. 18F-fluorodeoxyglucose positron emission tomography in patients with pulmonary sarcoidosis. Respirology 2011; 16(4): 713-20. 10.1111/j.1440-1843. 2011.01966.x [doi] 10.1111/j.1440-1843.2011.01966.x [doi].
76. Vorselaars AD, Verwoerd A, van Moorsel CH et al. Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis. Eur Respir J 2014; 43(2): 602-9. 09031936.00055213 [pii].10.1183/09031936.00055213 [doi] 09031936.00055213 [pii].10.1183/09031936.00055213 [doi].
77. Blankstein R, Osborne M, Naya M et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 2014; 63(4): 329-36. S0735-1097(13)05455-7 [pii]. 10.1016/j.jacc.2013.09.022 [doi] S0735-1097(13)05455-7 [pii]. 10.1016/j.jacc.2013.09.022 [doi].
78. 18F- fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis. J Nucl Cardiol 2014; 21(1): 166-74. 10.1007/s12350-013- 9828-6 [doi] 10.1007/s12350-013-9828-6 [doi].
79. Reich JM. Neoplasia in the etiology of sarcoidosis. Eur J Intern Med 2006; 17: 81-7. 10.1016/j.ejim.2005.09.023 10.1016/j.ejim.2005.09. 023.
80. Reich JM, Mullooly JP, Johnson RE. Linkage analysis of malignancy-associated sarcoidosis. Chest 1995; 107: 605-13.
81. 18F-fluorodeoxyglucose in sarcoidosis patients. Chest 2007; 131: 1019-27. 10.1378/chest.06-2160 10.1378/chest.06-2160.
82. Yamada Y, Uchida Y, Tatsumi K et al. Fluorine-18-fluorodeoxyglucose and carbon-11-methionine evaluation of lymphadenopathy in sarcoidosis. J Nucl Med 1998; 39: 1160-6. (Pubitemid 28326144)
83. ten Bokum AM, Hofland LJ, de Jong G et al. Immunohistochemical localization of somatostatin receptor sst2A in sarcoid granulomas. Eur J Clin Invest 1999; 29: 630-6. eci498 [pii] eci498 [pii].
84. Kwekkeboom DJ, Krenning EP, Kho GS et al. Somatostatin receptor imaging in patients with sarcoidosis. Eur J Nucl Med 1998; 25: 1284-92. (Pubitemid 28446055)
85. Larson SM, Erdi Y, Akhurst T et al. Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis. Clin Positron Imaging 1999; 2: 159-71.
86. Alavi A, Newberg AB, Souder E, Berlin JA. Quantitative analysis of PET and MRI data in normal aging and Alzheimer's disease: atrophy weighted total brain metabolism and absolute whole brain metabolismas reliable discriminators. J Nucl Med 1993; 34: 1681-7. (Pubitemid 23295377)
87. Kim TM, Paeng JC, Chun IK et al. Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma. Cancer 2013; 119: 1195-202. 10.1002/cncr.27855 10.1002/cncr.27855.
88. 18F-FDG PET/CT of liver metastases in colorectal cancer. Eur J Nucl Med Mol Imaging 2012; 39: 1858-67. 10.1007/s00259-012-2233-6 10.1007/s00259-012-2233-6.
89. Chen HH, Chiu NT, Su WC et al. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Radiology 2012; 264: 559-66. 10.1148/radiol.12111148 10.1148/radiol.12111148.
90. 18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma. J Nucl Med 2012; 53: 1506-13. 10.2967/jnumed.111.101402 10.2967/jnumed.111.101402.
91. 18F-fluorodeoxyglucose positron emission tomography. Intern J Gynecol Cancer 2012; 22: 1226-33. 10.1097/IGC.0b013e318260a905 10.1097/IGC. 0b013e318260a905.
92. 18F-fluoro-deoxyglucose. Seminars in nuclear medicine 1981; 11: 24-31.
93. Berkowitz A, Basu S, Srinivas S et al. Determination of whole-body metabolic burden as a quantitative measure of disease activity in lymphoma: a novel approach with fluorodeoxyglucose-PET. Nucl Med Commun 2008; 29: 521-6. 10.1097/MNM.0b013e3282f813a4 10.1097/MNM.0b013e3282f813a4.
94. Bural GG, Torigian DA, Burke A et al. Quantitative assessment of the hepatic metabolic volume product in patients with diffuse hepatic steatosis and normal controls through use of FDG-PET and MR imaging: a novel concept. Mol Imaging Biol 2010; 12: 233-9.10.1007/s11307-009-0258-4 10.1007/s11307-009-0258- 4.
95. Nawaz A, Saboury B, Basu S et al. Relation between popliteal-tibial artery atherosclerosis and global glycolytic metabolism in the affected diabetic foot: a pilot study using quantitative FDG-PET. J Amer Podiatr Med Assoc 2012; 102: 240-6. 102/3/240 [pii] 102/3/240 [pii].
96. Mehta NN, Torigian DA, Gelfand JM et al. Quantification of atherosclerotic plaque activity and vascular inflammation using [18-F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT). Journal of visualized experiments: JoVE 2012; 63: e3777. 10.3791/3777 10.3791/3777.
97. 18F-FDG-PET/CT: a pilot study. Ann Nucl Med 2014; 28: 53-9. 10.1007/s12149-013-0780-y 10.1007/s12149-013-0780-y.
98. Saboury B, Salavati A, Brothers A et al. FDG PET/CT in Crohn's disease: correlation of quantitative FDG PET/CT parameters with clinical and endoscopic surrogate markers of disease activity. Eur J Nucl Med Mol Imaging 2014; 41(4): 605-14. 10.1007/s00259-013-2625-2 10.1007/s00259-013-2625-2.
99. 18F-FDG PET/CT". J Nucl Med 2014; 55(2): 350-1.10.2967/jnumed. 113.130138 10.2967/jnumed.113.130138.
100. Salavati A, Basu S, Heidari P, Alavi A. Impact of fluorodeoxyglucose PET on the management of esophageal cancer. Nucl Med Commun 2009; 30: 95-116. 10.1097/MNM.0b013e32831af20410.1097/MNM.0b013e32831af204.
101. Kwee TC, Basu S, Saboury B et al. Functional oncoimaging techniques with potential clinical applications. Frontiers in bioscience (Elite edition) 2012; 4: 1081-96.
102. Torigian DA, Zaidi H, Kwee TC et al. PET/MR imaging: technical as pects and potential clinical applications. Radiology 2013; 267: 26-44. 10.1148/radiol.13121038 10.1148/radiol.13121038.
103. Ahmed Shamim S, Torigian DA, Kumar R. PET, PET/CT, and PET/MR Imaging Assessment of Breast Cancer. PET Clinics 2008; 3: 381-93.
104. Hustinx R, Torigian DA, Namur G. Complementary Assessment of Abdominopelvic Disorders with PET/CT and MRI. PET Clinics 2008; 3: 435-49.
105. Katz S, Ferrara T, Alavi A, Torigian DA. PET, CT, and MR Imaging for Assessment of Thoracic Malignancy: Structure Meets Function. PET Clinics 2008; 3: 395-410.
106. Goldberg MF, Chawla S, Alavi A et al. PET and MR Imaging of Brain Tumors. PET Clinics 2008; 3: 293-315.
107. Boss A, Bisdas S, Kolb A et al. Hybrid PET/MRI of intracranial masses: initial experiences and comparison to PET/CT. J Nucl Med 2010; 51: 1198-205.10.2967/jnumed.110.074773 10.2967/jnumed.110.074773.
108. Schwenzer NF, Stegger L, Bisdas S et al. Simultaneous PET/MR imaging in a human brain PET/MR system in 50 patients-current state of image quality. Eur J Radiol 2012; 81: 3472-8. 10.1016/j.ejrad.2011.12.027 10.1016/j.ejrad.2011.12. 027.
109. Cho ZH, Son YD, Kim HK et al. Observation of glucose metabolism in the thalamic nuclei by fusion PET/MRI. J Nucl Med 2011; 52: 401-4. 10.2967/jnumed.110.081281 10.2967/jnumed.110.081281.
110. Salamon N, Kung J, Shaw SJ et al. FDG-PET/MRI coregistration improves detection of cortical dysplasia in patients with epilepsy. Neurology 2008; 71: 1594-601. 10.1212/01.wnl.0000334752.41807.2f 10.1212/01.wnl.0000334752.41807.2f.
111. Nawaz A, Torigian DA, Siegelman ES et al. Diagnostic performance of FDG-PET, MRI, and plain film radiography (PFR) for the diagnosis of osteomyelitis in the diabetic foot. Mol Imaging Biol 2010; 12: 335-42. 10.1007/s11307-009-0268-2 10.1007/s11307-009-0268-2.
112. El-Haddad G, Kumar R, Pamplona R, Alavi A. PET/MRI depicts the exact location of meniscal tear associated with synovitis. Eur J Nucl Med Mol Imaging 2006; 33: 507-8. 10.1007/s00259-005-0034-x 10.1007/s00259-005-0034-x.
113. 18F-FDG PET-MRI of the hand in rheumatoid arthritis: initial results. Clinical Rheumatology 2011; 30: 1247-50. 10.1007/s10067-011-1777-3 10.1007/s10067-011-1777-3.
114. Syed IS, Feng D, Harris SR et al. MR imaging of cardiac masses. Magn Reson Imaging Clin N Am 2008; 16: 137-64. vii. 10.1016/j.mric.2008.02.009 10.1016/j.mric.2008.02.009.
115. Probst S, Seltzer A, Spieler B et al. The appearance of cardiac metastasis from squamous cell carcinoma of the lung on F-18 FDG PET/CT and post hoc PET/MRI. Clin Nucl Med 2011; 36: 311-2. 10.1097/RLU.0b013e31820a9fd1 10.1097/RLU.0b013e31820a9fd1.
116. Nensa F, Poeppel TD, Beiderwellen K et al. Hybrid PET/MR imaging of the heart: feasibility and initial results. Radiology 2013; 268: 366-73. 10.1148/radiol.13130231 10.1148/radiol.13130231.